Caleb is my second of three children. He was diagnosed with type 1 diabetes at the age of three in January 2007. He has used the OmniPod Insulin Management System since April 2007 and the DexCom Continuos Glucose Monitor since September 2009.
It was a big news day yesterday for FDA approval of diabetes devices.
The U.S. Food and Drug Administration today approved Medtronic’s MiniMed 670G hybrid closed looped system, the first FDA-approved device that is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses in people 14 years of age and older with type 1 diabetes.
Read yesterday’s full news release here.
I’m excited about this announcement for two reasons. First, this approval was received about six months before it was expected. I’m used to news coming later than predictions, not sooner. This is at least the second time the FDA has impressed me. The first time is when it approved the DexCom Share Receiver much sooner than expected. I’m optimistic that this is indicative of a great trend with the FDA.
Secondly, it’s another great step closer to a fully closed loop artificial pancreas system.
The 670G is a hybrid closed loop system. It will monitor glucose levels and adjust basal insulin to keep blood sugar as close to 120 as possible. Using this pump will still require carb counting, manually initiating meal boluses and corrections, and manually adjusting basal insulin to compensate for activity. This system is mono-hormonal: it uses only insulin, no glucagon. To me, the greatest benefit of this system may be for managing overnight basals.
For more information about this exciting announcement, here are some articles I found useful:
Updated 10/1/2016 to include this link to Diabetes Mine article describing what this pump is and what it is not. NEWSFLASH: FDA Approves First-Ever Pre-Artificial Pancreas from Medtronic!
A Sweet Life: How the Medtronic 670G Artificial Pancreas Works: FAQ
and also a lively discussion over at TuDiabetes.